<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="50924">Sorafenib</z:chebi> is a small molecule inhibitor of RAF kinase, VEGFR-2, c-KIT, and FLT3 </plain></SENT>
<SENT sid="1" pm="."><plain>In this randomized phase I study, eligible patients had relapsed/refractory <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), and one prior induction regimen, or were age &gt;65 with untreated <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) or <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="50924">Sorafenib</z:chebi> was given orally for 28 days (cont) or 14 days (int) every 4 weeks at three dose levels (100, 200, and 400 mg BID); 300 mg cont was also tested </plain></SENT>
<SENT sid="3" pm="."><plain>Forty-two patients were enrolled (median age 71 [37-82]; prior chemotherapy: 22) </plain></SENT>
<SENT sid="4" pm="."><plain>Dose-limiting toxicity (DLT) was: 100 mg BID: 0/7 patients; 200 mg BID: 2/12 patients; 400 mg BID: 1/17 patients </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="50924">Sorafenib</z:chebi> 400 mg cont was not tolerated in this population: 6/8 received &lt;14 days of treatment due to toxicity; no DLT was seen with 300 mg cont </plain></SENT>
<SENT sid="6" pm="."><plain>One CR was seen in a patient with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with FLT3-ITD </plain></SENT>
<SENT sid="7" pm="."><plain>Flow cytometry studies suggest that <z:chebi fb="0" ids="50924">sorafenib</z:chebi> inhibits ERK phosphorylation via c-KIT </plain></SENT>
<SENT sid="8" pm="."><plain>The recommended phase II dose in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> is 300 mg BID continuously, and testing in combination and in FLT3-ITD <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> is warranted </plain></SENT>
</text></document>